Delivery Order SPE2DB20D1050-SPE2DB25FH53M
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,356.71 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampule 2.5ml pharmaceutical supplies. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 18, 2025, issued on September 17, 2025. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,583.60 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml on August 21, 2025. This firm fixed-price delivery order, which is not set-aside, was competitively awarded and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $30,564.64 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml) on November 3, 2025, with completion scheduled for November 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the vendor's ongoing pharmaceutical supply relationship with the federal government. The contract is performed at AmerisourceBergen's...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) at a ceiling value of $6,286.98. This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor. The performance location is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL pharmaceutical product. This is a firm fixed price delivery order with a ceiling value of $2,583.60 and an ultimate completion date of July 28, 2025. The contract was awarded without a set-aside designation through competitive procurement, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $18,547.65 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and fulfills this order through its corporate office location at the same address....
- The Defense Logistics Agency awarded a delivery order valued at $12,871.03 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product for pulmonary disease treatment. The contract was competitively awarded without set-aside designation under a firm fixed price arrangement, with completion scheduled for November 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a $2,599.62 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency has awarded a delivery order valued at $18,388.41 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml vials). This firm fixed-price, non-set-aside delivery order was awarded on May 8, 2025, with an ultimate completion date of May 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This award represents a...
- SPE2DB20D1050Indefinite Delivery Contract
- SPE2DB20D1050-SPE2DB25FH53MDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,805.20 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5ml) on March 12, 2025, with an ultimate completion date of March 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor through its comprehensive IDC with DLA. This prime contract vehicle enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, and vaccines. The Pulmozyme delivery order reflects the company's ongoing role in fulfilling critical pharmaceutical needs for the Defense Health Agency and other government healthcare systems through competitively awarded delivery orders under this expansive contract framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 3/12/25 |